The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).
Ho Yeong Lim
Consultant or Advisory Role - Bayer (U)
Chia-Jui Yen
No relevant relationships to disclose
Won-Young Tak
No relevant relationships to disclose
Jeong Heo
No relevant relationships to disclose
Hye Jin Choi
No relevant relationships to disclose
Cheng-Yao Lin
No relevant relationships to disclose
Jung-Hwan Yoon
No relevant relationships to disclose
Chiun Hsu
No relevant relationships to disclose
Kun-Ming Rau
No relevant relationships to disclose
Ronnie Tung Ping Poon
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Winnie Yeo
No relevant relationships to disclose
Joong-Won Park
Consultant or Advisory Role - Advisory Board Member
Honoraria - Symposium Presentation
Miah Hiang Tay
No relevant relationships to disclose
Wen Son Hsieh
No relevant relationships to disclose
Christian Kappeler
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Prabhu Rajagopalan
Employment or Leadership Position - Bayer
Heiko Krissel
Employment or Leadership Position - Bayer
Stock Ownership - Bayer